Online inquiry

IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2873MR)

This product GTTS-WQ2873MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CCR4 gene. The antibody can be applied in Tropical spastic paraparesis, Adult T cell leukemia/lymphoma (ATL) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_005508.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1233
UniProt ID P51679
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2873MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10581MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY-3127804
GTTS-WQ13935MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-2810
GTTS-WQ9905MR IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA KB-003
GTTS-WQ11286MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEDI4893
GTTS-WQ2627MR IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 592
GTTS-WQ14515MR IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SA-237
GTTS-WQ2298MR IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ALXN-1210
GTTS-WQ8645MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HuMax-AXL-ADC
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW